



IFW

**PATENT APPLICATION**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of

Docket No: Q86824

Ikuya SEKI, et al.

Allowed: August 2, 2006

Appln. No.: 10/528,771

Group Art Unit: 1654

Confirmation No.: 2031

Examiner: David Lukton

Filed: March 23, 2005

For: COMPOUND BINDING TO LEUKOCYTES AND MEDICINAL COMPOSITION  
CONTAINING THE COMPOUND IN LABELED STATE AS THE ACTIVE  
INGREDIENT

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. §§ 1.97 and 1.98**

**MAIL STOP ISSUE FEE**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, along with a copy of the corresponding September 22, 2006 Communication from a The Patent Office of the People's Republic of China, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

U.S. Appln. No.: 10/528,771

Atty. Docket No.: Q86824

A full copy of the reference, BAIDOO, K.E., et al., High-Affinity No-Carrier-Added 99mTc-Labeled Chemotactic Peptides for Studies of Inflammation in Vivo, Bioconjugate Chem. 1998 Mar-Apr; 9(2): 208-17, listed in the Information Disclosure Statement filed on November 13, 2006 is now being submitted.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

SUGHRUE MION, PLLC  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860


WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: November 14, 2006

Respectfully submitted,

  
Susan J. Maek  
Registration No. 30,951

## **INFORMATION DISCLOSURE** **STATEMENT BY APPLICANT**

*Complete if Known*

Application Number	10/528,771
Confirmation Number	2031
Filing Date	March 23, 2005
First Named Inventor	Ikuya SEKI
Art Unit	1654
Examiner Name	David Lukton
Attorney Docket Number	Q86824

Sheet

1

of

1

[illegible][illegible][illegible]**Date Considered**

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov), MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to indicate here if English language Translation is attached.